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887-4 Suboptimal  Platelet Inhibition With Tirof iban in Patients 
Undergoing Coronary Intervention for Unstable Angina 
Daniel Softer, William W. O'Neill, Kishore J. Harjai, Murat Karatepe, Judith Boura, Simon 
R. Dixon, Robert D. Safian, Cindy L, Grines, Jeffrey W. Moses, Issam Mousse, Gary S. 
Roubin, William Beaumont Hospital, Royal Oak, Michigan, Lenox Hill Heart and Vascular 
Institute, New York, New York. 
Background: The current dosing regimen for tirOfiban during percutaneous coronary 
intervention (PCI) is based on limited platelet inhibition (PI) studies using 5pmol o1 ADP 
as a platalet agonist. We hypothesized that, when using 20~mol of ADP, the current 
tirofiban dose may not result in optimal PI in pts undergoing PCI for unstable angina 
(UA). 
Methode: We prospectively measured PI in 102 pte (62 ± 10 yrs, 78% males) who 
received tirofiban (10mcg/kg, 0.15mcg/kg/min) during PCI. All pts received ASA and clo- 
pidogrel prior to the procedure. PI was measured 15 min following tirofiban bolus with the 
IchorTM point-of-care platetet analyzer (Helena Laboratories, Beaumont, TX), using 
20~.mol of ADP. Pts were classified into 2 groups: Gr I-n=61 with stable or class I Breun- 
wald unstable angina (UA) and Gr II-n=41 with class II or Ill UA. 
Results: Gr II pts were more likely to have received b blockers (88 vs 66%, p=0.012), IV 
hepaifn (93 vs 18%, p<0.0001), and to have a recent MI (34 vs 0%, p<0.0001). The 
groups were similar in other respects. PI and % of pts who achieved >70% PI in each Gr 
are shown below. In multivariate analysis, class II or III UA was independently associated 
with <70% PI (OR 11.9, 95%CI 2.5 to 57.3, p=0.002). 
Conclusions: The current dose of tirofiban used in pts undergoing PCI for UA appears 
to be sub-optimal. Our findings may explain the mixed results of recent trials with 
tirofiban in such pts. Large-scale, prospective studies should evaluate whether tirofiban 
dose adjustment will have an impact on clinical outcome. 
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887-5 Tirofiban, Eptifibatide, and Abciximab in Minimizing 
Myocardial Damage During High-Risk Coronary 
Intervention: Final Results of the TEAM Pilot Trial 
Samin K. Sharma, Annapoorna S. Kini, Nohelia Perez, Javed Suleman, Edward A. 
Fisher, Jonathan D. Marmur, Merwin Richard, The Mount Sinai Medical Center, New 
York, New York. 
Background: The diverse results of various randomized PCI trials of GP lib/Ills inhibi- 
tors (GPI) may be due to different levels of platelet inhibiton (PI) achieved by a particular 
GPI agent. TEAM pilot trial is a double blind, randomized study of the three GPI during 
high-risk clinical (rest angina, post MI) or lesion (type C, ostial, calcified, thrombotic, mul- 
tivessel intervention) PCI settings. TEAM study hypothesis was that with similar levels of 
PI (>90%) all three agents will have an equal class effect in reducing myocardial damage 
and 30-day MACE. 
Methods: We analyzed 180 PCI patients randomized to one of the three arms: tirofiban 
(T / RESTORE dose), eptifibatide (E / PURSUIT dose), and abciximab (A / EPILOG 
dose), with similar baseline clinical, angiographic, and procedural characteristics. 
Patients with <90% PI (by RPFA with Ultegra device) after 10 min of GPI infusion, 
received additional half bolus of the blinded agent prior to PCI. 
Results: In 232 lesions treated, angiogrephic success was 97.3% and procedural suc- 
cess 98.9%, 0.5/2.2% major/minor TIMI bleeding complications, 2.2/1.1% mild/severa 
thrombocytopenia nthe entire group and were similar between the three agents. 
Variable Tirofiban Eptifibatide Abciximab p 
n=56 n=61 n=63 
Need for additional bolus (%) 58.9 31.1 53.9 0.004 
Final PI pdor to PCI (%) 93+4 93+3 93_+4 NS 
Any CKMB ^  (%) 15.1 13.9 14.2 NS 
Peak CKMB (U/L) 10.3_+13.2 12.2+21.7 10.7_+11.4 NS 
Peak troponin I ng/mL 4.2_+8.9 3.7_+9.1 5.9_+9.2 NS 
Peak ACT (sac) 248-+22 254_+28 264+16 NS 
30-day MACE (%) 4.7 4.6 4.9 NS 
Conclusion: PCI patients with high-risk clinical/lesions require increased GPI dose com- 
pared to the recommended ose for an optimal PL With this strategy, all three GPI had 
similar effect on myocardial salvage and 30-day MACE and was not associated with 
increase in bleeding. 
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887-6 Initial Experience With a Novel Direct Factor Xa Inhibitor 
in Percutaneous Coronary Intervention 
John H. Alexander, Christopher K. Dyke, Richard C. Becker, Hongqui Yang, Thomas L. 
Robertaon, Satoshi Kunitada, Linda A, Zillman, Eric A. Cohen, Edwin G. Bovill, Peter B. 
Berger, Michael Lincoff, Judith S. Hochman, Paul W. Armstrong, Neal S. Kleiman, Robert 
A. Herdngton, Duke University Medical Center, Durham, North Carolina. 
Background. Anticoagulatlon with unfractlonated heparin in coronary intervention (PCI) 
has significant limitations and upstream inhibition of the coagulation cascade may have 
advantages. We investigated use of a direct factor Xa inhibitor, DX-9065a (DX), in PCI. 
Methods. Patients undergoing elective, native vessel, PCI were randomized (4:1) to 
open label DX or UFH. Using pharmacodynamic modeling, three sequential, weight- 
adjusted, double-bolus and infusion DX regimens were formulated to rapidly achieve and 
maintain plasma concentrations of at least (lower 95% CI) 100ng/ml, 75ng/ml, and 
150ng/ml. UFH was dosed as 70-80 U/kg with, or 100 U/kg without, GP lib/Ilia inhibitors. 
Enrollment in the 75ng/ml phase was discontinued [n=6] after a case of severe intracoro- 
nary thrombus formation. Coagulation parameters were acquired dudng PCI, 15 minutes 
after 2 nd DX bolus. *Present prior to enrollment but extended. Results. Mean age was 58 
years, 82% were male, median PCI duration was 0.3 hours, and 84% and 92% received 
GP lib/Ilia inhibitors and stents. Vessel and lesion sevedty were matched across groups. 
Results are shown in table. Coagulation parameters are median (25 th, 75th). Conclu- 
sions. Direct factor Xa inhibition in PCI using concentration targeted DX-9065a dosing is 
feasible, effective, and provides a measurable anticoagulant effect using bedside INR. 
Further trials 1o define the optimal dose and establish the safety and efficacy of DX- 
9065a in PCI and acute coronary syndromes are needed, 
DX DX DX UFH 
75n~ml 100n~ml 150n~ml n=23 
n=6 n=45 n=45 
Dissection 0 0 2 (4.4%) 0 
Abrupt closure 0 0 0 0 
No reflow 0 0 0 0 
Thrombus 1 (17%) 0 1 (2.2%)* 0 
Side branch loss 0 3 (6.7%) 0 0 
Distal embolization 0 0 0 0 
Major bleed 0 1 (2.2%) 0 0 
Minor bleed 1 (17%) 1 (2.2%) 1 (2.2%) 0 
Transfusion 0 1 (2.2%) 0 0 
Death 0 0 0 O 
MI 1 (17%) 3 (6.7%) 0 0 
Stroke 0 0 0 0 
Revasc 0 0 O O 
ACT (seconds) 149 171 187 NA 
(137,161) (146,188) (150,246) 
n=3 n=8 n=6 
Whole blood 1.9 2.6 3.2 NA 
Bedside INR (1.8,25.5) (2.5,2.7) (3,0,3.2) 
DX-9065a (ng/ml) 123 192 pending NA 
(117,126) (183,250) 
Anti-Xa (IU/ml) 0.33 0.36 pending NA 
(0.26,0.39) (0.32,0.38) 
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888-1 Long-Term Clinical Fol low-Up After Palmaz-Schstz 
Stent Placement In Native Coronary Arteries 
Takeshi Kimura, Kenichi Abe, Yoshihisa Nakagawa, Hiroyoshi Yokoi, Masashi Iwabuchi, 
Naoya Hamasaki, Hideyuki Nosaka, Masakiyo Nobuyoshi, Kokura Memorial Hospital, 
Kitakyushu, Japan. 
Background: Although coronary stenting has been proven to be effective in reducing clin- 
ical cardiac events up to 3 years (yrs), longer-term efficacy and safety have not yet been 
established. Method: To evaluate longer-term (8-11yrs) outcome, follow-up information 
was analyzed in 405 patients (pts) or 424 lesions with clinically successful coronary 
stenting in native coronary artedes (Age; co4~9, Male; 79%, Diabetes; 29%, Multivesset 
disease; 56%, Prior myocardial infarction(MI); 55%, Prior coronary adery bypass sur- 
gery(CABG); 6%, Multivesssl peroutaneous coronary intervention(PCI); 23%, Ejection 
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fraction<40%;12%, LAD/RCNCx/LMCA; 43% / 43% / 10% / 3%, Restenotic lesion; 
42%). Mean follow-up interval was 8.4±1.4 yrs among 298 surviving pts. Follow-up rate 
was 98% at 7 yrs. Achievement of stabilization of steoted lesion was defined as freedom 
from target lesion (TL)-PCI/CABG/Death during initial 14 months (Primary stabilization) 
or during 14 months after the last TL-PCI (Secondary stabilization). Result: Primary sta- 
bilization was achieved in 317 pts (78%). Among 61 pts (15%) with early TL-PCI, sec- 
ondary stabilization was achieved in 56 pts (92%) with average number of 1.5 repeated 
PCI procedures. Stabilization was achieved in 92% of pts overall. Event-free survival 
rates at 8yrs were as follows: Cardiac death 90%, Death 76 %, Deeth/MI/CABG 67%, 
Death/MI/CABG/TL-PCI 57%, Death/MI/CABG/Any-PCI 37%. Among 35 episodes of Q 
wave MI, only 3 was related to the stented lesion. Late TL-PCI, defined as that performed 
after achievement of stabilization, was uncommon but increased slightly beyond 5 yrs (1 
% at 5 yrs, 6% at 8 yrs). Among 181 pts undergoing clinically driven very late (>4 yrs) fol- 
low-up angiography , targets of the repeated revascularization procedure were more 
often new lesions (41%) than stanted lesions (11%). Conclusion: Stabilization of stented 
lesions was achieved in the majority of pts with limited numbers of TL-PCI in this cohort 
of pts with classical indication of coronary stenting. Once stabilization was achieved, late 
clinical events related to stanted lesions were uncommon. The efficacy and safety of cor- 
onary stanting appeared to be sustained at 8-11 yrs of follow-up. 
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888-2 In Saphenoua Vein Grafts Bigger Is Not Significantly 
Better: An Intravaecular Ultrasound Study 
Ioannis lakovou. G. Dangas, A. Abizaid, G. Mintz, R. Mehran, Y. Kobayashi, D. Ashby, M. 
Hirose, S. lyer, G. W. Stone, M. Collins, G. Roubin, M. Astatkie, J. W. Moses, M. B. Leon, 
Cardiovascular Research Foundation, Lenox Hill Heart & Vascular Institute, New York, 
New York. 
Background. Larger final lumen dimensions after PCI in native coronary arteries lead to 
lower restenosis rates. However, the impact of stsnt expansion - assessed by intravascu- 
lar ultrasound (IVUS) -on clinical results of PCI in saphenous vein grafts (SVG) is not 
known. 
Methods. We identified 226 consecutive patients who underwent IVUS-guided stenting of 
229 de novo SVG lesions; they were divided in two groups based on final steot cross- 
sectional area (CSA): Group I (stent CSA <100% reference lumen CSA, n=176 patients, 
178 lesions) and Group II (stant CSA >100% reference lumen CSA, n= 50 patients, 51 
lesions). 
Results. Baseline patient characteristics were similar between the two groups with the 
exception of shorter lesions in Group II patients (Table). More aggressive stent implanta- 
tion (Group II pts) was associated with (1) increased rates of in-hospital non-Q wave MI 
(CK-MB • 5 times normal) and (2) higher 1-year event rates. 
Conclusions. Aggressive stent expansion in SVG lesions is associated with higher post- 
procedure non-Q-wave MI and, unlike native arteries, no improvement in clinical rsstano- 
sis (repeat target lesion revascularization, TLR). A less aggressive stent implantation 
strategy in SVG than in native coronary lesions seems appropriate. 
Group I Group II p 
n=176 n=50 
Age 68 ± 91 68 ± 10 0.7 
Vein Graft Age 13 ± 56 102 ± 56 0.2 
Diabetes 32.2% 38.5% 0.4 
Degenerated SVG 51.1% 42.1% 0.5 
Reference Vessel Size (mm) 3.55 ± 0.7 3.47 ± 0.8 0.6 
Lesion Length (mm) 10.8 ± 8.6 7.2 ± 5.2 0.01 
Final Lumen CSA (mm2) 9.2 ± 3.3 10.4 ± 3.3 0.01 
No-reflow 1.7% 1% 1.0 
In-hospital Non QWMI 17.4% 29.4% 0.05 
In-hospital MACE 1.1% 0.0% 1.0 
1 -year mortality 10.2% 14.9% 0.4 
1 -year MI 8% 26.2% 0.003 
1-year TLR 22.6% 31% 0.3 
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888-3 Does Stsnting Benefit Patients With Left Anterior 
Descending Infarction? Results From the CADILLAC 
Trial 
Eulooio Garcia, David Cox, Cindy L Grines, Raul Moreno, James Tcheng, Thomas 
Stuckey, Barry Rutherford, J. Mc Lean, John Carrol, Alexandra Lansky, Gregg W. Stone, 
for the CADILLAC investigators, Hospital Gregorio Marsnon, Madrid, Spain. 
Background: Previous studies have shown that patients with AMI involving the proximal 
LAD have worse clinical outcomes compared to non proximal LAD infarction. Whether 
stant placement can improve the outcomes compared to balloon angioplasty for proximal 
LAD infarction remains unknown. 
Methods: Two thousand eighty two AMI patients of any age with less than 12 hours from 
symptom onset (excluding cardiogenic shock) were randomized at 76 international sites 
to PTCA (n=517), PTCA plus abciximab (n--529), stem (n=512) and stent plus abclximab 
(n=524). CASS site determination of proximal LAD Infarction was verified by the core lab. 
Results: Proximal LAD Infaretion ocurred in 21.2% (n=441/2,082) of patients in this tdal. 
Compared to non-proximal LAD, patients with proximal LAD infarction had increased 
mortality at 30 days (3.8% vs 1.7%, p=0.008), 6 months (6.8% vs. 2.6%, p<0.001 ), and at 
1 year (7.5% vs. 3.4%, p<0.001 ). They also had a higher incidence of MACE at 6 months 
(21.1% vs. 12.3%, p<0.001) and at 1 year (23.6% vs. 15.1%, p<0.001). Among patients 
with proximal LAD infarction, those treated with stent underwent less often repeated tar- 
get vessel reveecularization at 6 months (12.0% vs 23.2%, p=0.002), and at 1 year 
(16.6% vs. 32.6%, p<0,001), while no difference was observed between the two groups 
in the incidence of the other major adverse cardiac events at 30 days, 6 months and 1 
year. 
Conclusion: in the CADILLAC study, more than 20% of patients presented with proximal 
LAD infarction. These patients were at higher risk for adverse events. In this subgroup, 
those treated with stent had less target vessel revasculerization at mid and long-term fol- 
low-up. The adjunctive ffect of abciximab in this subgroup will be available for presenta- 
tion. 
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888-4 Prolongat ion of Activated Clotting Time (ACT) With 
Tlrof lban Versus Abc ix imab and Its Aa=mclation to 
Outcome: Results From TARGET 
David J. MoliterPo. Richard A. Lange, Christian Harem, Bernhard Meier, Peter M. 
DiBattiste, Nasser Lakkis, Jia Gang, Derek P. Chew, David M. Cohen, Gregg W. Stone, 
Laura Demopoulos, Eric J. Topoi, Cleveland Clinic Foundation, Cleveland, Ohio. 
Background: Placabo-controlled studies have shown abciximab to prolong the ACT by 
-30 seconds while small-molecule agents (tirofiban and optiflbetide) have little or no 
impact. Separately, it is uncertain if higher procedural ACT's would narrow any outcome 
difference between abciximab and tirofiban. 
Methods: TARGET randomized 4,809 patients to abciximab or tirofiban in a double-blind 
fashion. Heparin administration was recommended as a <= 70U/kg bolus with an aim to 
prolong the ACT to approximately 250 seconds. We analyzed heparin dose, peak proce- 
dural ACT's, ischemic outcome, and bleeding events. 
Results: The mean total heparin dose for tirofiban and abclximab groups were 6316 units 
and 6372 units, respectively, and this corresponded to average weight-adjusted oses of 
75.0 and 74.5 U/kg. The resultant median (26th, 75th) peek ACT's for tirofiban and abcix- 
imab groups were 281 (250, 324) and 283 (253, 325). The 50-day ischemic (death, MI, 
uTVR) and major bleeding events for ACT according to ACT quartilee are listed (table). 
Conclusions: Given very similar heparin doses, tiroflben and abcixtmab were associated 
with nearly identical ACT results. Bleeding events were higher, but ischemic events were 
not lowered with more prolonged ACT values. Differences in clinical outcome between 
the agents cannot be attributed to the level of anticoaguletion. 
Median ACT 
Death, MI, uTVR (%) Major Bleeding (%) 
"13rofiban Abclximab Tirofiban Abciximab 
Q1 226s 6.8 6.3 0.2 0.4 
Q2 266s 8.5 8.5 0.7 0.5 
Q3 502s 8.9 5.9 0.9 0.7 
Q4 3~s  7.1 4.9 2.2 1.1 
11:30 a.m. 
888-5 Glycemic Control  and in Stent Reaten~is  In Patients 
With Diabetes Mellitus 
Hironori Mivoshi, Hiroshi Kamihata, Yasuo Sutani, Yo Nagahama, Koichi Yamada, Kengo 
Hataba, Yoshleki Tsuka, Toshiji Iwaseka, Kansai Medical University-Cardiovascular 
Center, Monguchi, Japan. 
Background: Diabetes is an adverse dsk factor for in-stent restenosis. Whether optimal 
glycemio control at coronary intervention reduces this risk is unknown. 
Methods: We reviewed clinical and angiogrephic 6 month outcomes of 116 consecutive 
diabetics with successful stent placement between 7/94 and 3/00 at our institution. Dia- 
betics with known HbAlc level at coronary intervention ware classified as having optimal 
(HbAlc<7.0%, n=57) or sub-optimal (HbAlc>7.0%, n--59) glycemic control. We evalu- 
ated MACE (Death, MI, re-PTCA and CABG) and angiogrephic results for each diabetic 
group. 
Results: The two groups were comparable with respect to age, gender, coronary risk pro- 
file except diabetes, and clinical presentation. Vessel characteristics, and pre- and post- 
procedure QCA results were also similar for the two groups except multi-vessel disease 
which was more prevalent in the diabetics with sub-optimal control (51% vs 30%, 
p--O.02). Angiographic restenosis rate and TLR during the follow-up were significantly 
higher in diabetics with sub-optimal control than those with optimal control (50% vs 33%, 
p--0.06 and 38% vs 21%, p=0.03, respectively). MACE at 6-month were similar for the 
two groups. At one year, MACE was significantly higher in diabetics with sub-optimal 
control than those with optimal control (39% vs 21%, p=0.03). 
Conclusions: Diabetics with optimal glycemic control at coronary intervention reduces 
restenosis rate, and consequently led to favorable long-term results compared with sub- 
optimal control. Optimal glycemic control should be considered as an important medical 
target in the prevention of in-stent restenosis. 
